|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2003-12-17
|
|
pubmed:abstractText |
The survival benefit associated with first-line chemotherapy in advanced lung cancer led to the need for second-line chemotherapy. Docetaxel (Taxotere) has proven efficacy in both settings. This study evaluated the safety and efficacy of two doses of docetaxel in patients with non-small-cell lung cancer who had failed first-line platinum-based chemotherapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
pubmed-author:BrechotJ MJM,
pubmed-author:BreevaL GLG,
pubmed-author:ClouetPP,
pubmed-author:DebieuvreDD,
pubmed-author:DepierreAA,
pubmed-author:DucoloneAA,
pubmed-author:LebeauBB,
pubmed-author:LemarieEE,
pubmed-author:MilleronBB,
pubmed-author:Moro-SibilotDD,
pubmed-author:PujolJ LJL,
pubmed-author:QuoixEE,
pubmed-author:VayletFF,
pubmed-author:VergnenegreAA,
pubmed-author:ZalcmanGG
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
38-44
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:14679117-Adult,
pubmed-meshheading:14679117-Aged,
pubmed-meshheading:14679117-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:14679117-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:14679117-Disease Progression,
pubmed-meshheading:14679117-Dose-Response Relationship, Drug,
pubmed-meshheading:14679117-Female,
pubmed-meshheading:14679117-Humans,
pubmed-meshheading:14679117-Infusions, Intravenous,
pubmed-meshheading:14679117-Lung Neoplasms,
pubmed-meshheading:14679117-Male,
pubmed-meshheading:14679117-Middle Aged,
pubmed-meshheading:14679117-Neoplasm Recurrence, Local,
pubmed-meshheading:14679117-Neutropenia,
pubmed-meshheading:14679117-Safety,
pubmed-meshheading:14679117-Survival Analysis,
pubmed-meshheading:14679117-Taxoids,
pubmed-meshheading:14679117-Time Factors,
pubmed-meshheading:14679117-Treatment Failure,
pubmed-meshheading:14679117-Treatment Outcome
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Randomised, multicentre phase II study assessing two doses of docetaxel (75 or 100 mg/m2) as second-line monotherapy for non-small-cell lung cancer.
|
|
pubmed:affiliation |
Hôpital Lyautey, Strasbourg, France. elisabeth.quoix@chru-strasburg.fr
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Multicenter Study,
Clinical Trial, Phase II
|
